CSL - Operating Profit

Stock Price
96.37
Daily Change
-1.59 -1.62%
Monthly
-29.87%
Yearly
-60.14%
Q2 Forecast
96.11

CSL reported $2.64B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
CSL USD 2.64B 1.97B Dec/2025
Curis USD -7.88M 4.63M Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024